In contrast, the sensitivity to cisplatin treatment of the shBTG2 ovarian cancer cells was weaker than that of the shCtrl group, while the sensitivity of the GV-BTG2 group was stronger than that of the GV-Ctrl group. Here, BTG2 is linked to ovarian cancer.